Nuvig Secures 1 Million Series B Funding from Major Pharmaceutical Companies for Autoimmune Treatments

The pharmaceutical industry is investing heavily in the emerging field of immunomodulatory therapies, contributing 1 million to Nuvig Therapeutics’ Series B funding round. On Thursday, the California-based biotech firm revealed that the financing was co-led by Sanofi Ventures, alongside contributions from the investment branches of Bayer, Novo Holdings, and Bristol Myers Squibb.

Nuvig is pioneering a first-of-its-kind Fc fragment immunomodulator, intended to enhance autoimmune regulation without the immune suppression typically associated with various autoimmune treatments. The primary candidate, NVG-2089, is currently in Phase I trials for chronic inflammatory demyelinating polyneuropathy (CIDP). The company has obtained Fast Track designation for NVG-2089 in bullous pemphigoid, a rare autoimmune condition that leads the immune system to attack healthy skin cells.

The new funding from the Series B round is set to enhance the development of NVG-2089, progressing it from Phase I into proof-of-concept Phase II trials across various indications, along with advancing the preclinical pipeline, according to the announcement. Simultaneously, partners from Sanofi Ventures and two other investment firms will be invited to join the company’s Board of Directors.

launch two and a half years ago, which raised million, led by Novo Holdings with support from Bristol Myers Squibb and others.